The role of quizartinib in the treatment of acute myeloid leukemia
- PMID: 24070241
- DOI: 10.1517/13543784.2013.842973
The role of quizartinib in the treatment of acute myeloid leukemia
Abstract
Introduction: Approximately one-third of the patients with acute myeloid leukemia (AML) harbor internal tandem duplication (ITD) in the gene encoding FMS-like tyrosine kinase 3 (FLT3-ITD), which is associated with poor prognosis. Over the course of the last decade, several FLT3 inhibitors have been developed. Nevertheless, the pharmacokinetic limitations of some of these compounds as well as their potency have limited their therapeutic efficacy. Quizartinib (AC220) is a second-generation FLT3 inhibitor that has shown promising activity in AML in Phase II clinical trials.
Areas covered: The pharmacokinetic, mechanism of action and resistance as well as clinical studies of quizartinib in AML are reported here in detail.
Expert opinion: Quizartinib is potent and selective FLT3 tyrosine kinase inhibitor with significant activity in both FLT3-mutant and wild-type AML. The quality and duration of achievable response thus far seen with this agent is suboptimal. Quizartinib in combination with chemotherapy might result in improved outcome and results of these trials are eagerly awaited. In addition, quizartinib in combination with other agents tackling the bone marrow microenvironment and FLT3 cooperative pathways may enhance response to quizartinib.
Similar articles
-
Quizartinib (AC220): a promising option for acute myeloid leukemia.Drug Des Devel Ther. 2019 Apr 8;13:1117-1125. doi: 10.2147/DDDT.S198950. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31114157 Free PMC article. Review.
-
Quizartinib: a new hope in acute myeloid leukemia, an applied comprehensive review.Future Oncol. 2024;20(35):2791-2810. doi: 10.1080/14796694.2024.2399425. Epub 2024 Sep 19. Future Oncol. 2024. PMID: 39297694 Review.
-
Quizartinib for the treatment of acute myeloid leukemia.Expert Opin Pharmacother. 2020 Dec;21(17):2077-2090. doi: 10.1080/14656566.2020.1801637. Epub 2020 Aug 9. Expert Opin Pharmacother. 2020. PMID: 32772726 Review.
-
FLT3 inhibitor quizartinib (AC220).Leuk Lymphoma. 2019 Aug;60(8):1866-1876. doi: 10.1080/10428194.2019.1602263. Epub 2019 Apr 18. Leuk Lymphoma. 2019. PMID: 30997851 Review.
-
Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia.Future Oncol. 2019 Dec;15(34):3885-3894. doi: 10.2217/fon-2019-0353. Epub 2019 Sep 27. Future Oncol. 2019. PMID: 31559849 Review.
Cited by
-
Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells.Int J Mol Sci. 2015 Jan 7;16(1):1266-92. doi: 10.3390/ijms16011266. Int J Mol Sci. 2015. PMID: 25574601 Free PMC article.
-
Quizartinib (AC220): a promising option for acute myeloid leukemia.Drug Des Devel Ther. 2019 Apr 8;13:1117-1125. doi: 10.2147/DDDT.S198950. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31114157 Free PMC article. Review.
-
Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death.Cell Death Dis. 2018 Jan 26;9(2):138. doi: 10.1038/s41419-017-0170-9. Cell Death Dis. 2018. PMID: 29374185 Free PMC article.
-
Protein Kinase Inhibitors as Therapeutic Drugs in AML: Advances and Challenges.Curr Pharm Des. 2017 Nov 16;23(29):4303-4310. doi: 10.2174/1381612823666170703164114. Curr Pharm Des. 2017. PMID: 28671056 Free PMC article. Review.
-
BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.Mol Cancer Ther. 2014 Oct;13(10):2315-27. doi: 10.1158/1535-7163.MCT-14-0258. Epub 2014 Jul 22. Mol Cancer Ther. 2014. PMID: 25053825 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
